Showing 281-290 of 9754 results for "".
How to Leverage New Technologies to Achieve Better Balance
https://practicaldermatology.com/topics/practice-management/how-to-leverage-new-technologies-to-achieve-better-balance/22992/Technology to date may not have streamlined patient care and practice management as expected, but emerging solutions are paving the way for greater efficiency, accuracy and ease-of-use.An Update on the Use of Minocycline for the Treatment of Acne
https://practicaldermatology.com/columns/clinical-focus-1/an-update-on-the-use-of-minocycline-for-the-treatment-of-acne/23201/Advances in formulation technology have led to the development of a stable topical minocycline that recently received FDA approval. Here’s what you should know.DermWireTV: Epsolay Approval; See My Skin from Vaseline; Jori Launch; Novartis Grant for Farmworker Justice
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-epsolay-approval-see-my-skin-from-vaseline-jori-launch-novartis-grant-for-farmworker-justice/20094/Vaseline’s new See My Skin Campaign aims to help consumers of all skin types recognize skin diseases and connect them with dermatologists who can help manage them. Uchenna Okereke, MD discusses the initiative. Farmworker Justice, an organization dedicated to empowering farmworkers to improve immigraMichael Gold Honored, CSF Highlights, Anxiety Linked to Skin Disease
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-michael-gold-honored-csf-highlights-anxiety-linked-to-skin-disease/18720/From bloodless blephs to nutraceuticals, innovative approaches to patient care take the spotlight at Cosmetic Surgery Forum each year. This year, the meeting introduced new topics and new speakers, says CSF founder and Practical Dermatology Chief Cosmetic Surgery Editor, Dr. Joel Schlessinger. Dr. MDermWireTV: Vtama Approved; Monkey Pox; AbbVie Scholarship; LRP Pride in Dermatology
https://practicaldermatology.com/topics/psoriasis/dermwiretv-vtama-approved-monkey-pox-abbvie-scholarship-lrp-pride-in-dermatology/20097/Vtama (tapinarof) cream 1% from Dermavant is approved for the treatment of psoriasis in adults. Tapinarof is an aryl hydrocarbon receptor agonist. As a public health service, VisualDx is offering pictures of monkey pox and disease information to support clinical decision-making. Forty-five scholarshDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)DermWireTV: Enbrel/AD Link, LGBTQ Health and Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-enbrelad-link-lgbtq-health-and-dermatology/19624/Signals in accumulated data for Enbrel seem to suggest that etanercept may have a protective effect against Alzheimer’s disease, the Washington Post reported earlier this month. The AAD position statement on Sexual and Gender Minority Health in Dermatology says that, “Dermatologists can and should cDermWireTV: Spevigo for GPP; Derms on Acne Experience; IFPA Takes PsO to the Gaming World; La Roche-Posay at the US Open
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spevigo-for-gpp-derms-on-acne-experience-ifpa-takes-pso-to-the-gaming-world-la-roche-posay-at-the-us-open/20136/Boehringer Ingelheim’s Spevigo is the first FDA-approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spesolimab is a novel, selective antibody that blocks the activation of the interleukin-36 receptor. Dermatologists, dermatology physician assistants, and dermatologyDermWireTV: Pfizer, AbbVie JAKs for AD; Spray-on-Skin; Lubriderm Scholarships
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pfizer-abbvie-jaks-for-ad-spray-on-skin-lubriderm-scholarships/20043/For the treatment of refractory moderate-to-severe atopic dermatitis, FDA has approved Pfizer’s Cibinqo (abrocitinib) for adults and AbbVie’s Rinvoq (upadacitinib) for patients 12 and older. Researchers at the Houston Methodist Research Institute have paired their patented RNA technologies with AvitDermWireTV: AbbVie to Acquire Allergan, Duobrii Launches, SDPA at 25
https://practicaldermatology.com/topics/psoriasis/dermwiretv-abbvie-to-acquire-allergan-duobrii-launches-sdpa-at-25/19629/In a deal with an equity value of approximately $63 billion, AbbVie has agreed to acquire Allergan. The new company is positioned for new growth platforms and a diversified revenue base; the deal will be immediately accretive to earnings per share, AbbVie says. The Society of Dermatology Physician A